TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE C

NCT04443010: A Study to Evaluate the Safety and Efficacy of the Tumor-targeting Human Antibody-cytokine Fusion Protein L19TNF Plus Standard Temozolomide Chemoradiotherapy in Patients With Newly Diagnosed Glioblastoma

Sponsor: Philogen S.p.A. · Phase: PHASE1/PHASE2 · Area: ONCOLOGY · Target Enrollment: 226 pts

Competing Trials Overlap

2 Active Trials

Excess Burn Exposure

$12,566,400

Rescue Site Savings

+$8,285,970

Unlock Full NCT04443010 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT04443010 Rescue Dossier →